Analysts Anticipate Repligen Co. (NASDAQ:RGEN) to Post $0.73 EPS

Brokerages forecast that Repligen Co. (NASDAQ:RGENGet Rating) will post earnings per share (EPS) of $0.73 for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Repligen’s earnings, with the lowest EPS estimate coming in at $0.66 and the highest estimate coming in at $0.80. Repligen posted earnings of $0.79 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 7.6%. The firm is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Repligen will report full year earnings of $3.14 per share for the current fiscal year, with EPS estimates ranging from $3.09 to $3.26. For the next fiscal year, analysts anticipate that the business will report earnings of $3.67 per share, with EPS estimates ranging from $3.50 to $4.12. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Repligen.

Repligen (NASDAQ:RGENGet Rating) last released its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.20. The company had revenue of $206.40 million for the quarter, compared to analyst estimates of $185.48 million. Repligen had a net margin of 19.86% and a return on equity of 11.13%. Repligen’s revenue for the quarter was up 44.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.68 EPS.

Several research analysts have recently weighed in on the stock. SVB Leerink lowered their price objective on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating on the stock in a research note on Friday, February 18th. Craig Hallum lowered their price objective on shares of Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 price objective on the stock. in a research note on Monday, February 21st. Finally, StockNews.com began coverage on shares of Repligen in a report on Thursday, March 31st. They set a “hold” rating for the company. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $285.57.

In related news, Director Thomas F. Ryan, Jr. sold 2,000 shares of Repligen stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total transaction of $396,060.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of RGEN. Allspring Global Investments Holdings LLC bought a new stake in Repligen in the 4th quarter valued at about $218,643,000. Norges Bank bought a new stake in shares of Repligen during the 4th quarter worth approximately $138,881,000. Franklin Resources Inc. lifted its holdings in shares of Repligen by 25.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,063,338 shares of the biotechnology company’s stock worth $307,294,000 after acquiring an additional 217,697 shares during the period. Millennium Management LLC lifted its holdings in shares of Repligen by 186.2% during the 4th quarter. Millennium Management LLC now owns 309,482 shares of the biotechnology company’s stock worth $81,963,000 after acquiring an additional 201,342 shares during the period. Finally, Impax Asset Management Group plc lifted its holdings in shares of Repligen by 31.6% during the 4th quarter. Impax Asset Management Group plc now owns 813,012 shares of the biotechnology company’s stock worth $214,295,000 after acquiring an additional 195,300 shares during the period. 86.82% of the stock is owned by hedge funds and other institutional investors.

Repligen stock opened at $149.96 on Friday. The firm has a market capitalization of $8.16 billion, a PE ratio of 59.27 and a beta of 0.98. The company’s 50-day moving average is $166.51 and its 200-day moving average is $208.10. Repligen has a fifty-two week low of $137.21 and a fifty-two week high of $327.32.

About Repligen (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.